Literature DB >> 17803655

PIK3CA mutation and amplification in human lung cancer.

Koji Okudela1, Masaya Suzuki, Shinji Kageyama, Tomoyasu Bunai, Kiyoko Nagura, Hisaki Igarashi, Kazuya Takamochi, Kazuya Suzuki, Takeshi Yamada, Hiroshi Niwa, Riuko Ohashi, Hiroshi Ogawa, Hiroki Mori, Hitoshi Kitamura, Takeshi Kaneko, Toshihiro Tsuneyoshi, Haruhiko Sugimura.   

Abstract

To explore the significance of phosphatidylinositol-3-kinase, catalytic, alpha (PIK3CA) in the carcinogenesis in human lung, mutations and copy number changes were investigated in 148 Japanese patients with primary cancer of the lung. For biological validation, the effects of exogenously expressed wild-type and mutated PIK3CA were studied in an immortalized human airway epithelial cell line. Mutations in PIK3CA were found in five (3.6%) of the 139 available patients, and copy number gains were found in 21 (18.3%) of 115 patients, respectively. Overall, mutations or copy number gains were detected in 24 of the 106 patients (22.6%) for whom results in both analyses were available. The prevalence of copy number gains was higher in men, smokers, and in patients with squamous cell carcinoma than in the opposite categories. The copy number changes showed a trend toward higher prevalence in the earlier stages (P = 0.038). Interestingly, the presence of mutations and of copy number alterations were mutually exclusive in the present patients, implying that both entail equivalent oncogenic potential. Over-expressed wild-type PIK3CA and its two common mutants, K545E and H1047R, significantly enhanced the anchorage-independent growth activity and migration activity of immortalized airway epithelium 16HBE14o- cells, but the effects of the K545E and H1047R mutants were more remarkable than those of the wild-type. The present demonstrates an important role of PIK3CA in human lung carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17803655     DOI: 10.1111/j.1440-1827.2007.02155.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  55 in total

1.  Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice.

Authors:  L V Sequist; R S Heist; A T Shaw; P Fidias; R Rosovsky; J S Temel; I T Lennes; S Digumarthy; B A Waltman; E Bast; S Tammireddy; L Morrissey; A Muzikansky; S B Goldberg; J Gainor; C L Channick; J C Wain; H Gaissert; D M Donahue; A Muniappan; C Wright; H Willers; D J Mathisen; N C Choi; J Baselga; T J Lynch; L W Ellisen; M Mino-Kenudson; M Lanuti; D R Borger; A J Iafrate; J A Engelman; D Dias-Santagata
Journal:  Ann Oncol       Date:  2011-11-09       Impact factor: 32.976

Review 2.  Oncogenic mutations of PIK3CA in human cancers.

Authors:  Yardena Samuels; Todd Waldman
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

Review 3.  Genetic changes in squamous cell lung cancer: a review.

Authors:  Rebecca S Heist; Lecia V Sequist; Jeffrey A Engelman
Journal:  J Thorac Oncol       Date:  2012-05       Impact factor: 15.609

Review 4.  Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer.

Authors:  Po Yee Yip
Journal:  Transl Lung Cancer Res       Date:  2015-04

Review 5.  Inhibitors of phosphatidylinositol-3-kinase in cancer therapy.

Authors:  Nathan T Ihle; Garth Powis
Journal:  Mol Aspects Med       Date:  2010-02-20

Review 6.  Treatment of nonsmall cell lung cancer: overcoming the resistance to epidermal growth factor receptor inhibitors.

Authors:  Corey A Carter; Giuseppe Giaccone
Journal:  Curr Opin Oncol       Date:  2012-03       Impact factor: 3.645

7.  PIK3CA mutation in Chinese patients with lung squamous cell carcinoma.

Authors:  Jinglin Yu; Hua Bai; Zhijie Wang; Zhigang Wei; Xiaosheng Ding; Jianchun Duan; Lu Yang; Meina Wu; Yuyan Wang; Jie Wang
Journal:  Chin J Cancer Res       Date:  2013-08       Impact factor: 5.087

8.  YEATS4 is a novel oncogene amplified in non-small cell lung cancer that regulates the p53 pathway.

Authors:  Larissa A Pikor; William W Lockwood; Kelsie L Thu; Emily A Vucic; Raj Chari; Adi F Gazdar; Stephen Lam; Wan L Lam
Journal:  Cancer Res       Date:  2013-10-29       Impact factor: 12.701

9.  Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients.

Authors:  Youngwook Kim; Peter S Hammerman; Jaegil Kim; Ji-ae Yoon; Yoomi Lee; Jong-Mu Sun; Matthew D Wilkerson; Chandra Sekhar Pedamallu; Kristian Cibulskis; Yeong Kyung Yoo; Michael S Lawrence; Petar Stojanov; Scott L Carter; Aaron McKenna; Chip Stewart; Andrey Y Sivachenko; In-Jae Oh; Hong Kwan Kim; Yong Soo Choi; Kwhanmien Kim; Young Mog Shim; Kyu-Sik Kim; Sang-Yun Song; Kook-Joo Na; Yoon-La Choi; D Neil Hayes; Jhingook Kim; Sukki Cho; Young-Chul Kim; Jin Seok Ahn; Myung-Ju Ahn; Gad Getz; Matthew Meyerson; Keunchil Park
Journal:  J Clin Oncol       Date:  2013-12-09       Impact factor: 44.544

10.  Expression of fibroblast growth factor receptor 1, fibroblast growth factor 2, phosphatidyl inositol 3 phosphate kinase and their clinical and prognostic significance in early and advanced stage of squamous cell carcinoma of the lung.

Authors:  Cigdem Usul Afsar; Berksoy Sahin; Meral Gunaldi; Emine Kılıc Bagir; Derya Gumurdulu; Refik Burgut; Melek Erkisi; Ismail Oguz Kara; Semra Paydas; Feryal Karaca; Vehbi Ercolak
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.